Two small privately held vaccines companies, Inviragen of the US and Singapore's SingVax, have merged to create an enlarged operation with a focus on vaccines for infectious diseases prevalent in developing countries.
The new firm retains the Inviragen name and will be headed by the co-founder and current CEO of that company,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?